vincristine + cisplatin + cyclophosphamide + etoposide + methotrexate

This is a multi-agent induction chemotherapy regimen utilized in the HeadStart4 clinical trial (NCT04182360) for newly diagnosed children under 10 years of age with medulloblastoma or other central nervous system (CNS) embryonal tumors. The regimen consists of vincristine, cisplatin, cyclophosphamide, etoposide, and high-dose methotrexate. It serves as the initial intensive treatment phase intended to reduce tumor volume prior to consolidation therapy with autologous hematopoietic progenitor cell rescue. The trial, led by Parth Patel, compares single versus tandem cycles of consolidation to improve survival outcomes in high-risk pediatric patients.

Other names

Induction chemotherapyHeadStart 4 Induction RegimenHeadStart4 Induction RegimenHeadStart-4 Induction RegimenInduction-Parth Patel-medulloblastoma-central nervous system embryonal tumor